GlassScriptPhysician profile
Brian Duke
NPI 1457195604
$7,374.09
in general payments reported to CMS, 2019-2025
60 companies · $5,070 in 2025
The $5,070 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,304 · 2025: $5,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,205 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,205.15 |
| Education | $168.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $598.40 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $476.16 | 2024-2025 | Calquence, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $452.75 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $452.32 | 2024-2025 | Libtayo, Lynozyfic |
| Incyte Corporation | $357.50 | 2024-2025 | Monjuvi, Zynyz, Jakafi |
| Celgene Corporation | $333.96 | 2024-2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $319.32 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $318.79 | 2024-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $314.17 | 2024-2025 | Erleada, Balversa, Darzalex |
| Daiichi Sankyo INC. | $240.53 | 2024-2025 | Enhertu, Datroway |
| Jazz Pharmaceuticals INC. | $235.48 | 2024-2025 | |
| Genzyme Corporation | $230.79 | 2024-2025 | |
| Stemline Therapeutics INC. | $187.17 | 2024-2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $164.97 | 2024-2025 | Monoferric |
| Lilly USA, LLC | $161.94 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $159.02 | 2025 | Polivy, Tecentriq, Venclexta |
| Ipsen Biopharmaceuticals, INC | $151.04 | 2024-2025 | Onivyde |
| Beone Medicines USA, INC. | $141.37 | 2025 | Brukinsa, Tevimbra |
| Pharmaessentia USA Corporation | $135.19 | 2024-2025 | Besremi |
| Eisai INC. | $111.75 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $109.69 | 2024-2025 | Orgovyx |
| Abbvie INC. | $107.03 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.32 | 2024-2025 | Ninlaro, Iclusig, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $94.24 | 2024-2025 | |
| Caris Mpi, INC. | $90.46 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $88.94 | 2025 | Xtandi |
| Kyowa Kirin, INC. | $87.06 | 2025 | |
| Tempus Ai, INC | $83.94 | 2025 | Xt Cdx |
| Alexion Pharmaceuticals, INC. | $83.71 | 2025 | Ultomiris |
| Glaxosmithkline, LLC. | $74.55 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Array Biopharma INC | $54.75 | 2025 | Braftovi, Mektovi, Tukysa |
| Syndax Pharmaceuticals, INC. | $50.92 | 2025 | |
| Deciphera Pharmaceuticals INC. | $49.59 | 2025 | Qinlock, Romvimza |
| Iovance Biotherapeutics, INC. | $49.54 | 2024-2025 | Amtagvi |
| Recordati_rare_diseases_inc. | $47.72 | 2024-2025 | Sylvant, Enjaymo |
| Acrotech Biopharma INC. | $41.86 | 2024-2025 | Beleodaq, Ryzneuta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.77 | 2025 | |
| Aveo Pharmaceuticals, INC. | $40.87 | 2025 | |
| Sobi, INC | $40.79 | 2025 | |
| Celltrion USA INC. | $37.60 | 2025 | Vegzelma |
| Exelixis INC. | $35.87 | 2024-2025 | Cabometyx |
| Genmab U.S., INC. | $35.11 | 2024-2025 | Epkinly |
| Spectrum Pharmaceuticals INC. | $32.49 | 2024-2025 | Rolvedon |
| Puma Biotechnology, INC. | $31.71 | 2024-2025 | |
| Coherus Oncology, INC. | $31.28 | 2024 | |
| Beigene USA, INC. | $28.98 | 2025 | Tevimbra, Brukinsa |
| Karyopharm Therapeutics INC. | $28.94 | 2025 | Xpovio |
| Amgen INC. | $23.35 | 2024 | |
| Sun Pharmaceutical Industries INC. | $22.62 | 2025 | |
| Blueprint Medicines Corporation | $22.58 | 2024 | Ayvakit |
| Tersera Therapeutics LLC | $21.53 | 2025 | Quzyttir |
| Amneal Pharmaceuticals LLC | $20.26 | 2025 | Alymsys |
| Gilead Sciences, INC. | $17.41 | 2025 | Trodelvy |
| Taiho Oncology, INC. | $16.75 | 2024 | |
| Geron Corporation | $16.55 | 2025 | Rytelo |
| Progenics Pharmaceuticals, INC. | $15.02 | 2025 | |
| Mirati Therapeutics, INC. | $14.58 | 2024 | Krazati |
| Apellis Pharmaceuticals, INC. | $14.51 | 2025 | Empaveli |
| Immunocore Limited | $14.17 | 2025 | Kimmtrak |
| Rigel Pharmaceuticals, INC. | $12.41 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.